Golden State Equity Partners’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-180,500
| Closed | -$44.4K | – | 1509 |
|
|
2026
Q1 | $44.4K | Sell |
180,500
-215,443
| -54% | -$85.7K | ﹤0.01% | 912 |
|
|
2025
Q4 | $166K | Sell |
395,943
-23,000
| -5% | -$12.2K | 0.03% | 483 |
|
|
2025
Q3 | $282K | Buy |
418,943
+27,000
| +7% | +$14.6K | 0.05% | 362 |
|
|
2025
Q2 | $212K | Buy |
391,943
+20,000
| +5% | +$11.9K | 0.04% | 403 |
|
|
2025
Q1 | $244K | Buy |
371,943
+46,259
| +14% | +$49K | 0.05% | 373 |
|
|
2024
Q4 | $332K | Buy |
325,684
+313,587
| +2,592% | +$573K | 0.06% | 316 |
|
|
2024
Q3 | $10.5K | Sell |
12,097
-185,019
| -94% | -$136K | 0.01% | 573 |
|
|
2024
Q2 | $70.6K | Buy |
+197,116
| New | +$107K | 0.01% | 398 |
|
|
2023
Q4 | $109K | Buy |
201,225
+34,960
| +21% | +$16.1K | 0.03% | 352 |
|
|
2023
Q3 | $99.7K | Buy |
166,265
+30,500
| +22% | +$32.7K | 0.03% | 330 |
|
|
2023
Q2 | $176K | Hold |
135,765
| – | – | 0.05% | 351 |
|
|
2023
Q1 | $239K | Buy |
+135,765
| New | +$387K | 0.13% | 177 |
|
|
2022
Q1 | $897K | Buy |
154,360
+10,592
| +7% | +$63K | 0.45% | 66 |
|
|
2021
Q4 | $1.08M | Buy |
143,768
+16,203
| +13% | +$141K | 0.54% | 46 |
|
|
2021
Q3 | $1.15M | Buy |
127,565
+257
| +0.2% | +$2.54K | 0.47% | 50 |
|
|
2021
Q2 | $1.52M | Buy |
127,308
+700
| +0.6% | +$7.92K | 0.59% | 37 |
|
|
2021
Q1 | $1.59M | Buy |
126,608
+2,791
| +2% | +$37.6K | 0.91% | 31 |
|
|
2020
Q4 | $1.93M | Buy |
+123,817
| New | +$1.45M | 1.33% | 16 |
|
Other funds holding SGMO
Golden State Equity Partners's SGMO Position: Q2 2026 in Review
Golden State Equity Partners sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 180,500 shares — an estimated $44.4K sold.
Golden State Equity Partners first reported a position in SGMO in Q4 2020 and held it in 18 quarters. The position peaked at $1.93M in Q4 2020. 2 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.
- Golden State Equity Partners reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
- Golden State Equity Partners sold 180,500 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $44.4K.
- Golden State Equity Partners first reported a position in SANGAMO THERAPEUTICS INC in Q4 2020 and held it in 18 quarters.
- Golden State Equity Partners's SANGAMO THERAPEUTICS INC position peaked at $1.93M in Q4 2020.
- 2 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.
Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.